BridgeBio Pharma, Inc. BBIO
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the "FDA") approval for three products. We believe our decentralized hub and spoke model enables us to achieve clinical proof-of-concept with speed and efficiency, demonstrated by an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug ("IND") submission. This efficiency allows us to work on a broad range of scientifically compelling therapies, including programs for underserved conditions which more traditional biopharmaceutical models might leave on the shelf but we believe can be developed on a Net Present Value ("NPV")-positive basis in our portfolio.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M | — | — | — |
| Cost of revenue | $21.0M | $3.9M | $2.4M | $3.4M | $3.1M | — | — | — | — | — |
| Gross profit | $481.1M | $218.0M | $6.9M | $74.2M | $66.6M | — | — | — | — | — |
| R&D | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M | $140.1M | $30.6M | — |
| SG&A | $531.2M | $288.9M | $150.6M | $143.2M | $192.2M | $145.7M | $94.4M | $43.6M | $13.3M | — |
| Total operating expenses | $1.03B | $814.9M | $616.7M | $589.9M | $646.3M | $482.7M | $306.8M | $183.7M | $43.9M | — |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M | -$474.5M | -$266.2M | -$183.7M | -$43.9M | — |
| Interest expense | $53.1M | $91.0M | $81.3M | $80.4M | $46.8M | $36.7M | $8.8M | $2.5M | $13.0K | — |
| Pre-tax income | -$732.5M | -$542.2M | -$653.3M | -$484.7M | — | $505.5M | $288.6M | $169.5M | $43.8M | — |
| Income tax | $435.0K | $1.2M | $0 | $0 | — | — | — | — | — | — |
| Net income | -$732.9M | -$543.3M | -$653.3M | -$484.6M | -$586.5M | -$505.5M | -$288.6M | -$169.5M | -$43.8M | — |
| EPS, basic | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | — | — | — | — |
| EPS, diluted | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | -2.12 | -1.00 | — |
| Shares, diluted (wtd. avg.) | 191.5M | 186.1M | 162.8M | 147.5M | 144.4M | 118.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M | $356.1M | $363.8M | $436.1M | $92.0M | — |
| Short-term investments | $17.4M | $0 | $0 | $51.6M | $393.7M | $251.0M | $182.2M | — | — | — |
| Receivables | $139.4M | $4.7M | $1.8M | — | — | — | — | — | — | — |
| Inventory | $26.8M | $0 | — | — | — | — | — | — | — | — |
| Total current assets | $797.7M | $720.7M | $477.6M | $548.9M | $888.9M | $642.8M | $568.6M | $445.2M | — | — |
| Property, plant and equipment | $5.4M | $7.0M | $11.8M | $14.6M | $30.1M | $20.3M | $5.6M | $1.6M | — | — |
| Other intangibles | $28.1M | $23.9M | $26.3M | $28.7M | $44.9M | $0 | — | — | — | — |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.01B | $703.6M | $631.7M | $464.9M | — | — |
| Accounts payable | $36.2M | $9.6M | $10.7M | $11.6M | $11.9M | $8.9M | $8.9M | $13.5M | — | — |
| Short-term debt | — | — | — | — | — | $1.5M | — | — | — | — |
| Total current liabilities | $288.0M | $154.4M | $143.8M | $121.4M | $135.1M | $95.6M | $60.4M | $32.6M | — | — |
| Long-term debt | $2.01B | $437.3M | $446.4M | $431.0M | $430.8M | $92.4M | $91.8M | $54.5M | — | — |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.7M | $155.7M | $87.6M | — | — |
| Retained earnings | -$3.82B | -$3.10B | -$2.56B | -$1.92B | -$1.44B | -$888.8M | -$440.0M | -$179.4M | -$48.7M | -$18.1M |
| Total equity | -$2.09B | -$1.47B | -$1.34B | -$1.24B | -$867.0M | $106.3M | $473.7M | $377.2M | $88.3M | $14.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M | -$399.7M | -$253.6M | -$136.6M | -$40.5M | — |
| Depreciation and amortisation | $5.4M | $6.1M | $6.5M | $6.8M | $5.8M | $1.5M | $859.0K | — | — | — |
| Stock-based compensation | $133.0M | $95.8M | $108.7M | $91.6M | $99.5M | $58.5M | $21.4M | $6.1M | $1.8M | — |
| Capital expenditure | $1.1M | $933.0K | $1.3M | $4.8M | $13.2M | $7.5M | $2.6M | $2.2M | $464.0K | — |
| Investing cash flow | -$24.5M | $60.8M | $54.0M | $453.1M | -$200.8M | -$53.0M | -$217.3M | -$21.0M | -$464.0K | — |
| Financing cash flow | $359.3M | $748.5M | $451.5M | -$13.1M | $736.4M | $447.2M | $398.8M | $501.5M | $113.0M | — |
| Dividends paid | — | — | — | — | — | — | $997.0K | — | $1.2M | — |
| Buybacks | $48.3M | $0 | $0 | $0 | $200.0M | $75.0M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016723.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Gross profit | — | — | — | — | — | $66.6M | $74.2M | $6.9M | $218.0M | $481.1M |
| Net income | — | -$43.8M | -$169.5M | -$288.6M | -$505.5M | -$586.5M | -$484.6M | -$653.3M | -$543.3M | -$732.9M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |